CureVac Shareholders Face Pivotal Merger Vote
Published on 11/19/2025 at 06:11 | Redaktion boerse-global.de
The future of CureVac as an independent entity now rests in shareholders’ hands as a decisive vote approaches. Investors will determine whether to approve a transformative acquisition by competitor BioNTech, marking a critical juncture for the pioneering mRNA company. With the deal’s completion pending final approval, stakeholders face a binary outcome that could either revitalize the biotech firm or conclude its standalone operations.
BioNTech has proposed an all-stock transaction valuing CureVac at approximately €1.25 billion. Should shareholders endorse the arrangement during the extraordinary general meeting scheduled for November 25, 2025, in Amsterdam, CureVac investors would receive a 4-6% stake in the combined entity. This valuation follows extensive restructuring efforts throughout 2024 and represents a strategic consolidation Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
